NCT04720612 (CIAO) is a Phase 2 clinical trial of Omalizumab in Covid19, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.

What drugs are being tested in NCT04720612?

Interventions in NCT04720612: Omalizumab, Placebo.

Is NCT04720612 still recruiting?

NCT04720612 is currently status unknown. Last updated 16 November 2022.

Last reviewed 2022-11-16 · How we verify

NCT04720612: CIAO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Immunologic Antiviral Therapy With Omalizumab

Status unknown Phase 2 Last updated 16 November 2022

What this trial tests

Phase 2 trial testing Omalizumab in Covid19 in 40 participants. Status unknown.

Timeline

15 October 2021

Primary endpoint
7 November 2022

16 December 2022

Quick facts

Lead sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	40
Start date	15 October 2021
Primary completion	7 November 2022
Estimated completion	16 December 2022
Sites	3 locations across Canada

Drugs / interventions tested

Omalizumab (omalizumab) — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate if omalizumab is effective in decreasing mortality in severe hospitalized COVID-19 cases.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Zhang J, Zhang H, Sun L. · · 2022 · cited 21× · PMID 35220888 · DOI 10.1080/19420862.2022.2031483
Consecutive intrabronchial administration of Wharton's jelly-derived mesenchymal stromal cells in ECMO-supported pediatric patients with end-stage interstitial lung disease: a safety and feasibility study (CIBA method).
Dominguez-Pinilla N, González-Granado LI, Gonzaga A, López Diaz M, et al · · 2025 · cited 3× · PMID 40188166 · DOI 10.1186/s13287-025-04289-3
COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)-a Randomized Controlled Clinical Trial.
Le M, Khoury L, Lu Y, Prosty C, et al · · 2024 · cited 2× · PMID 38560604 · DOI 10.1093/ofid/ofae102

Verify or expand the search:

Other trials of Omalizumab

Trials testing the same drug.

NCT07356713 — A Study to Find a Suitable Dose of Exl-111 for Further Research · Phase 1 · recruiting
NCT06934200 — Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels · Phase 2 · recruiting
NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
NCT06509334 — Trial of JYB1904 in Chronic Spontaneous Urticaria. · Phase 2 · recruiting
NCT06438757 — Trial of JYB1904 in Patients With Allergic Asthma · Phase 2 · active not recruiting

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials

Trials by the same sponsor.

NCT07439406 — Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy · Phase 2 · not yet recruiting
NCT07328971 — Vancomycin Taper to Prevent Recurrent Clostridioides Difficile · Phase 3 · not yet recruiting
NCT07556952 — Dex & Mastectomy Pain · Phase 4 · recruiting
NCT07069582 — Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women · Phase 1 · not yet recruiting
NCT07386171 — Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04720612 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre
Last refreshed: 16 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04720612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing